Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Botulinum Toxin Type A for Patients with Glabellar Lines
- 1 October 2003
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Plastic and Reconstructive Surgery
- Vol. 112 (4), 21S-30S
- https://doi.org/10.1097/01.prs.0000076504.79727.62
Abstract
The objective of this study was to evaluate the efficacy and safety of botulinum toxin type A for the treatment of glabellar lines. Patients with moderate or severe glabellar lines at maximal frown received intramuscular injections of placebo or 20 U of botulinum toxin type A (Botox; Allergan, Inc., Irvine, Calif.) distributed among five injection sites (one in the procerus muscle and two in each corrugator supercilii). Follow-up assessments were performed at 7, 30, 60, 90, and 120 days after injections. Efficacy measures were the physician's rating of glabellar line severity at maximal frown and at rest (none, mild, moderate, or severe) and the patient's global assessment of changes in glabellar lines, from +4 (100 percent better) to -4 (100 percent worse). A total of 273 patients were enrolled (botulinum toxin, 202 patients; placebo, 71 patients). All except five patients (botulinum toxin, two patients; placebo, three patients) completed the study. For the physician's rating at maximal frown, the responder rate (percentage of patients with severity ratings of none or mild in follow-up evaluations) for the botulinum toxin group peaked at 77 percent at day 30 and was significantly greater than that for the placebo group at every follow-up visit (p < 0.001). For the patient's assessment, the responder rate (percentage of patients with scores of +2 or more) for the botulinum toxin group peaked at 89 percent at day 30 and was significantly greater than that for the placebo group at every follow-up visit (p < 0.001). Rates of adverse events were similar for the two groups. The only adverse event with an incidence of >/=5 percent was headache (botulinum toxin, 11 percent; placebo, 20 percent). The incidence of blepharoptosis was 1 percent for the botulinum toxin group. Botulinum toxin type A was remarkably safe and effective in reducing glabellar lines.Keywords
This publication has 17 references indexed in Scilit:
- Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlledBMJ, 2001
- Pharmacotherapy with Botulinum Toxin: Harnessing Nature's Most Potent NeurotoxinPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2000
- Botulinum Toxin Type A as a Migraine Preventive TreatmentHeadache: The Journal of Head and Face Pain, 2000
- BOTULINUM TOXIN THERAPYThe Neurologist, 2000
- Botulinum A exotoxin for glabellar folds: A double-blind, placebo-controlled study with an electromyographic injection techniqueJournal of the American Academy of Dermatology, 1996
- Training guidelines for the use of botulinum toxin for the treatment of neurologic disordersNeurology, 1994
- Botulinum Toxin A for Hyperkinetic Facial Lines: Results of a Double-Blind, Placebo-Controlled StudyPlastic and Reconstructive Surgery, 1994
- Botulinum Toxin for the Treatment of Hyperfunctional Lines of the FaceJAMA Otolaryngology–Head & Neck Surgery, 1993
- Botulinum A Toxin for (Expressionistic) Ptosis Overcorrection After Frontalis SlingOphthalmic Plastic & Reconstructive Surgery, 1992
- Treatment of Glabellar Frown Lines with C. Botulinum‐A ExotoxinThe Journal of Dermatologic Surgery and Oncology, 1992